Over 60 companies across the globe claim to manufacture drug products / drug substances, By Roots Analysis

The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.

• A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service(s) offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish),  type of dosage form (solid and liquid), and installed capacity and batch size (if available).
• Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its service portfolio, continuous manufacturing capabilities and facilities, recent developments and an informed future outlook.
• An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements), scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). It also provides the regional distribution of the collaborations.

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:

• Purpose of Manufacturing

• In-House
• Contract service

• Scale of Operation

• Commercial
• Preclinical / Clinical

• Type of Continuous Manufacturing related Service
• API Manufacturing
• End Product manufacturing

• Type of Drug Molecule

• Biologic
• Small Molecule

• Type of dosage form

• Solid
• Liquid

• Key Geographical Regions
• North America
• Europe
• Asia Pacific

The Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 report features the following companies, which we identified to be key players in this domain:

• AbbVie Contract Manufacturing
• Ajinomoto Bio-Pharma Services
• Almac
• Boehringer Ingelheim BioXcellence
• Cambrex
• CordonPharma
• Hovione
• Kaneka
• Lonza
• Patheon
• SK biotek

Table of Contents

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Companies with Expertise in Continuous Manufacturing in North America: Profiles
 

6. Companies with Expertise in Continuous Manufacturing in Europe: Profiles
 

7. Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles
 

8. Recent Partnerships and Collaborations
 

9. Recent Expansions
 

10. Capacity Analysis
 

11. Academic Grant Analysis
 

12. Patent Analysis
 

13. Initiatives of Companies with In-House Continuous Manufacturing Capabilities
 

14. Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry

15. Case Study: Technology and Equipment Providers

16. Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes

17.  Market Forecast and Opportunity Analysis

18.  Conclusion

19.  Executive Insights

20.  Appendix 1: Tabulated Data

21.  Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]